Other Clinical Trial - Seroprevalence of SARS-Cov-2 Antibodies in Children

Status Completed

Clinical Trial Summary

It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.

Clinical Trial Description

Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome. The majority of coronaviruses cause disease in a specific host species but some have infected humans by cross-species transmission. This process has led to a number of severe outbreaks of human disease including severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012. From December 2019 a novel infection "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) was identified in the Wuhan region of China. The infection was identified as the causal factor in a growing number of severe cases of pneumonia. This disease was subsequently named coronavirus disease 2019 (COVID-19) by World Health Organisation (WHO). SARS-CoV-2 has been shown to cause severe disease similar to the previous SARS coronavirus from 2003. Severe disease is associated with pneumonia and damage to vital organs including lung, heart, liver, and kidney. Fortunately SARS-CoV-2 appears to cause only mild, or no, symptoms in children. The social distancing measures in the United Kingdom include the closure of schools and the cancelling of routine paediatric clinics. These drastic, but necessary, steps are likely to have a profound effect on the well-being of children. This study is required to determine what proportion of children have been exposed to SARS-Cov-2 and how many, if any, have neutralizing antibodies. The findings from this study could be used to inform public health decisions regarding the re-opening of schools and other services vital to the well-being of children. In addition the study will recruit children with paediatric multi-system inflammatory syndrome admitted to the Royal Belfast Hospital for Sick Children along with matched controls with other infections. ;

Study Design

Related Conditions & MeSH terms

Corona Virus Infection
Coronavirus Infections
COVID
Multisystem Inflammatory Syndrome in Children

Clinical Trial Details

NCT number	NCT04347408
Study type	Observational
Source	Queen's University, Belfast
Contact
Status	Completed
Phase
Start date	May 6, 2020
Completion date	November 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04558125` - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism	Phase 4
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Active, not recruiting	`NCT04420676` - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection	N/A
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Completed	`NCT04395911` - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections	N/A
Completed	`NCT04425317` - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients	N/A
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Withdrawn	`NCT04456426` - Characteristics of Patients With COVID-19 in Meta State, Colombia
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT04425720` - Use of Remote Monitoring for COVID-19 Patient	N/A
Completed	`NCT04419610` - RAS and Coagulopathy in COVID19	Early Phase 1
Completed	`NCT04546581` - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)	Phase 3
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04435327` - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting	`NCT04524156` - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2	N/A
Completed	`NCT04441710` - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT04392427` - New Antiviral Drugs for Treatment of COVID-19	Phase 3
Terminated	`NCT04614025` - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19	Phase 2
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.